Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051543 | 0.99 | KDM4E (0.66) | KDM4ECYP3A4CYP2C19HIF1APSMB5 | |
| SCHEMBL2540087 | 0.83 | KDM4E (0.78) | KDM4ECYP3A4CYP2C19HIF1AMAPT | |
| SCHEMBL14286188 | 0.81 | KDM4E (1.00) | KDM4ECYP3A4CYP2C19HIF1AMAPT | |
| SCHEMBL23674162 | 0.80 | PSMB5 (0.53) | KDM4ECYP3A4CYP2C19HIF1APSMB5 | |
| SCHEMBL2539722 | 0.78 | KDM4E (0.76) | KDM4ECYP3A4CYP2C19HIF1AMAPT | |
| SCHEMBL2534945 | 0.78 | CYP3A4 (0.76) | KDM4ECYP3A4CYP2C19HIF1AMAPT | |
| SCHEMBL2537741 | 0.76 | CYP3A4 (0.71) | KDM4ECYP3A4CYP2C19HIF1AMAPT | |
| SCHEMBL30927819 | 0.75 | SMN1; SMN2 (0.42) | KDM4ECYP3A4HIF1ATLR8SKP2 | |
| SCHEMBL7056719 | 0.74 | MAPT (0.41) | KDM4ECYP3A4CYP2C19HIF1APSMB5 | |
| SCHEMBL9252885 | 0.73 | MAPT (0.56) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| WO-2003026667-A1 | QUINAZOLINO- AND QUINOLINO- GUANIDINES AS LIGANDS FOR THE NEUROP EPTIDE FF (NPFF) RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | KDM4E 4560/4885CYP3A4 4583/4885CYP2C19 4185/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | KDM4E 3447/4885CYP3A4 3929/4885CYP2C19 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.